NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Anbio Biotechnology
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$3.27+0.14 (+4.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
Ownership
Who owns Anbio Biotechnology's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Lau | CEO | – | – | Apr 8, 2026 |
| Chris Tian | CBO | – | – | Apr 8, 2026 |
| Suki Song | CFO | – | – | Apr 8, 2026 |
| Michael W.C Zhang | Director | – | – | Jun 12, 2026 |
| David H. Hsu | Director | – | – | Jun 12, 2026 |
| Cany Xu | Director | – | – | Apr 8, 2026 |
| Nancy Hartzler | Director | – | – | Apr 8, 2026 |